TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34397084

Group type: EXPERIMENTAL
Intervention: Spin identified in RCT abstracts
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Spin in Results section
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Spin in Conclusions section
Number of subjects: 111

Group type: COMPARATOR
Intervention: International collaboration
Number of subjects: 111

Group type: COMPARATOR
Intervention: Trial registration
Number of subjects: 111
Study: 32957318

Group type: EXPERIMENTAL
Intervention: 10% hypertonic saline (HTS), 0.63 ml/kg, administered as a bolus via a central venous catheter, infused over 15 minutes
Number of subjects: 83

Group type: COMPARATOR
Intervention: 20% mannitol, 2 ml/kg, administered as a bolus via a central venous catheter, infused over 15 minutes
Number of subjects: 83
Study: 35790456

Group type: EXPERIMENTAL
Intervention: Disaster nursing and management education program (8 modules, theoretical and applied components)
Number of subjects: 131
Study: 33340721

Group type: EXPERIMENTAL
Intervention: 8-week specialized handgrip strength training program (TG)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 36
Study: 32508363

Group type: EXPERIMENTAL
Intervention: Adjunctive therapy with quetiapine or lamotrigine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monotherapy (lithium or divalproex)
Number of subjects: 0
Study: 36111589

Group type: EXPERIMENTAL
Intervention: Exufiber®
Number of subjects: 248

Group type: COMPARATOR
Intervention: Aquacel® Extra™
Number of subjects: 248
Study: 34181506

Group type: COMPARATOR
Intervention: Two doses of measles‐mumps‐rubella (MMR) vaccine
Number of subjects: 827

Group type: EXPERIMENTAL
Intervention: Not vaccinated against varicella
Number of subjects: 827

Group type: COMPARATOR
Intervention: MMR vaccine
Number of subjects: 827
Study: 32676780

Group type: COMPARATOR
Intervention: 1 g TXA via intravenous injection and 1 g TXA for external use (Group B)
Number of subjects: 599

Group type: COMPARATOR
Intervention: 10 mg rivaroxaban qd for 35 days after surgery (Group C)
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Combined treatment of TXA and rivaroxaban (Group D)
Number of subjects: 599
Study: 34365063

Group type: EXPERIMENTAL
Intervention: 15 mg IM ketorolac
Number of subjects: 110

Group type: COMPARATOR
Intervention: 60 mg IM ketorolac
Number of subjects: 110
Study: 32380977

Group type: EXPERIMENTAL
Intervention: Andrographolide (AP) 140 mg orally twice daily for 24 months
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Andrographolide (AP)
Number of subjects: 44
Study: 35537503

Group type: EXPERIMENTAL
Intervention: Left Atrial Appendage Occlusion (LAAO) with post-procedural dual antiplatelet therapy (DAPT)
Number of subjects: 609

Group type: COMPARATOR
Intervention: Control group (no antithrombotic therapy or DAPT as deemed appropriate)
Number of subjects: 609
Study: 32572472

Group type: EXPERIMENTAL
Intervention: TAK-003 vaccine
Number of subjects: 22
Study: 35325846

Group type: EXPERIMENTAL
Intervention: Topical 1% lidocaine with paracetamol
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Topical 1% lidocaine with ibuprofen
Number of subjects: 184

Group type: COMPARATOR
Intervention: Oral paracetamol alone
Number of subjects: 184

Group type: COMPARATOR
Intervention: Oral ibuprofen alone
Number of subjects: 184
Study: 33827502

Group type: EXPERIMENTAL
Intervention: Village Health Teams (VHTs) providing family planning services
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: VHTs of the same sex
Number of subjects: 250

Group type: COMPARATOR
Intervention: Older VHTs of the opposite sex
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Concerns about privacy and quality of care
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Concerns about contraceptive side effects
Number of subjects: 250
Study: 32216976

Group type: EXPERIMENTAL
Intervention: Videolaryngoscopy with protective cover of intraoral odontologic camera (PCIOC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Videolaryngoscopy without protective cover of intraoral odontologic camera (PCIOC)
Number of subjects: 30
Study: 32474062

Group type: EXPERIMENTAL
Intervention: Immediate restart of COC after taking UPA 30 mg
Number of subjects: 49

Group type: COMPARATOR
Intervention: Delayed restart of COC after taking UPA 30 mg
Number of subjects: 49
Study: 34617373

Group type: EXPERIMENTAL
Intervention: Outpatient telecare based on nurse-led non-invasive assessments (AMULET model)
Number of subjects: 605

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 605
Study: 33191835

Group type: EXPERIMENTAL
Intervention: Cyclosporine administered by continuous intravenous infusion for 5 days in a novel Cremophor/Kolliphor EL-free lipid emulsion, NeuroSTAT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 32346981

Group type: EXPERIMENTAL
Intervention: Immediate implant placement and provisionalization
Number of subjects: 36
Study: 34406551

Group type: EXPERIMENTAL
Intervention: HIV self-tests
Number of subjects: 752
Study: 33965603

Group type: EXPERIMENTAL
Intervention: CAL-DL-PDT (calcitriol followed by methyl aminolevulinate daylight photodynamic therapy)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: CAL-DL-PDT
Number of subjects: 42

Group type: COMPARATOR
Intervention: P-DL-PDT (placebo followed by methyl aminolevulinate daylight photodynamic therapy)
Number of subjects: 42

Group type: COMPARATOR
Intervention: P-DL-PDT
Number of subjects: 42
Study: 32049299

Group type: EXPERIMENTAL
Intervention: For-profit hospice agencies
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Nonprofit hospice agencies
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Overall quality of care
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Actionable criticisms
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Unactionable criticisms
Number of subjects: 100
Study: 35587086

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (TXA)
Number of subjects: 108
Study: 34818873

Group type: EXPERIMENTAL
Intervention: BT200 (0.18-48mg) subcutaneously
Number of subjects: 112
Study: 35706340

Group type: EXPERIMENTAL
Intervention: Remimazolam Tosilate
Number of subjects: 148

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 148
Study: 32024465

Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine combined with magnesium sulfate
Number of subjects: 11

Group type: COMPARATOR
Intervention: Epidural bupivacaine alone
Number of subjects: 11
Study: 36067018

Group type: EXPERIMENTAL
Intervention: TeleDiab group (telemedicine intervention)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual Care group (control)
Number of subjects: 200
Study: 33370154

Group type: EXPERIMENTAL
Intervention: Web-based MVPA intervention
Number of subjects: 205
Study: 36424261

Group type: EXPERIMENTAL
Intervention: D2+ lymphadenectomy
Number of subjects: 932

Group type: EXPERIMENTAL
Intervention: Large tumors (≥5 cm)
Number of subjects: 932

Group type: EXPERIMENTAL
Intervention: pT4
Number of subjects: 932

Group type: EXPERIMENTAL
Intervention: pN3
Number of subjects: 932

Group type: EXPERIMENTAL
Intervention: Undifferentiated histologic type
Number of subjects: 932
Study: 33653982

Group type: EXPERIMENTAL
Intervention: Erector spinae plane block (ESPB) with 40 ml of ropivacaine 0.5% at T9 level bilaterally
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no procedure performed)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Erector spinae plane block (ESPB)
Number of subjects: 70
Study: 32495449

Group type: EXPERIMENTAL
Intervention: Remimazolam (RMZ) 5 mg and 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Midazolam (MDZ) 2.5 mg and 5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Remimazolam (RMZ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Midazolam (MDZ)
Number of subjects: 0
Study: 35766126

Group type: EXPERIMENTAL
Intervention: Intravenous Regional Anesthesia (IVRA)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Periosteal Block
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Length of stay
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Patient satisfaction
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Clinician's assessed ease of the anesthetic technique
Number of subjects: 81
Study: 34081113

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 156

Group type: COMPARATOR
Intervention: HMB (1500 mg daily)
Number of subjects: 156
Study: 32654242

Group type: EXPERIMENTAL
Intervention: Maca (2 g/day for 12 weeks)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo (2 g/day for 12 weeks)
Number of subjects: 69
Study: 34105988

Group type: EXPERIMENTAL
Intervention: Active tDCS (2 mA, 20 min) applied over right/left dorsolateral prefrontal cortex (DLPFC) for 10 consecutive days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 30
Study: 34170946

Group type: EXPERIMENTAL
Intervention: Norway model (healthcare practitioners contact patients' family with information about kidney donation)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Home education model
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Transplant candidate advocate model
Number of subjects: 32
Study: 35162372

Group type: EXPERIMENTAL
Intervention: Exergaming session (EX)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Endurance exercise (ET)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Comparison of EX and ET
Number of subjects: 28
Study: 35226082

Group type: EXPERIMENTAL
Intervention: Portal messages encouraging a quit attempt with a link to asynchronous care (Group 2)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Portal messages encouraging a quit attempt without a link to asynchronous care (Group 1)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Portal messages from the health system with a link to asynchronous care (Group 4)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Portal messages from the health system without a link to asynchronous care (Group 3)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Asynchronous care offered
Number of subjects: 188

Group type: COMPARATOR
Intervention: In-person care offered
Number of subjects: 188
Study: 36163944

Group type: EXPERIMENTAL
Intervention: Pegcetacoplan (n=41) in PEGASUS study
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Pegcetacoplan (n=35) in PRINCE study
Number of subjects: 115

Group type: COMPARATOR
Intervention: Eculizumab (n=39) in PEGASUS study
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control treatment (n=18) in PRINCE study
Number of subjects: 115
Study: 33682614

Group type: EXPERIMENTAL
Intervention: Quitting drinking
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Reducing drinking to ≤7 drinks/week
Number of subjects: 163

Group type: COMPARATOR
Intervention: Continuing heavy drinking
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Quitting and reducing drinking
Number of subjects: 163
Study: 32898010

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Surgery first
Number of subjects: 140
Study: 33487260

Group type: EXPERIMENTAL
Intervention: Fasted low‐intensity aerobic exercise (50% VO2max) for 45 min followed by an isocaloric high‐fat meal.
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Fasted low‐intensity aerobic exercise (50% VO2max) for 45 min followed by a calorie deficit high‐fat meal.
Number of subjects: 21

Group type: COMPARATOR
Intervention: Rest and isocaloric high‐fat meal (60% lipids, 30% carbohydrates and 10% protein).
Number of subjects: 21
Study: 32467537

Group type: EXPERIMENTAL
Intervention: Incentive spirometry (IS)
Number of subjects: 95
Study: 34738474

Group type: EXPERIMENTAL
Intervention: Music-guided exercise intervention (n = 13), individualized music playlist, twice daily for 5 days.
Number of subjects: 26

Group type: COMPARATOR
Intervention: Active control group (n = 13), exercise brochure, same exercises at same intervals.
Number of subjects: 26
Study: 33743490

Group type: EXPERIMENTAL
Intervention: Genetic-fuzzy logic model for measuring stroke volume
Number of subjects: 92
Study: 32568111

Group type: EXPERIMENTAL
Intervention: Recommendations by a movement disorder specialist
Number of subjects: 91

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 91
Study: 33341915

Group type: EXPERIMENTAL
Intervention: MLH model using PET/MRI radiomics and machine learning
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: MBCR model combining MLH, PSA, and clinical stage values
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: MOPR model combining MLH, PSA, and clinical stage values
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard routine analysis based on PSA, biopsy Gleason score, and TNM staging
Number of subjects: 52

Group type: COMPARATOR
Intervention: [68Ga]Ga-PSMA-11 SUVmax analysis
Number of subjects: 52
Study: 32770491

Group type: EXPERIMENTAL
Intervention: Aphakic intraoperative aberrometry (IA) measurements
Number of subjects: 2

Group type: COMPARATOR
Intervention: Aphakic/pseudophakic intraoperative aberrometry (IA) measurements
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Aphakic IA measurements
Number of subjects: 2

Group type: COMPARATOR
Intervention: Aphakic/pseudophakic IA measurements
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Pseudophakic IA measurements
Number of subjects: 2
Study: 36386606

Group type: EXPERIMENTAL
Intervention: Intensive smoking cessation program (SCP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abbreviated smoking cessation program (SCP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparator group (general population of adult smokers)
Number of subjects: 0
Study: 33891379

Group type: EXPERIMENTAL
Intervention: Bimekizumab (320 mg every 4 weeks for 56 weeks)
Number of subjects: 478

Group type: COMPARATOR
Intervention: Adalimumab (40 mg every 2 weeks for 24 weeks, then bimekizumab every 4 weeks to week 56)
Number of subjects: 478
Study: 33011968

Group type: EXPERIMENTAL
Intervention: Dual triggering with 10,000 units of hCG plus 0.2 mg of triptorelin
Number of subjects: 160
Study: 32739240

Group type: EXPERIMENTAL
Intervention: MICS + CCI
Number of subjects: 49

Group type: COMPARATOR
Intervention: CCI only
Number of subjects: 49

Group type: COMPARATOR
Intervention: MICS + CCI and CCI only
Number of subjects: 49
Study: 35776835

Group type: EXPERIMENTAL
Intervention: Tapentadol (50 mg)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Oxycodone (10 mg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 34358344

Group type: EXPERIMENTAL
Intervention: FC plus low-dose oxytocin
Number of subjects: 220

Group type: COMPARATOR
Intervention: FC plus placebo
Number of subjects: 220
Study: 33872652

Group type: EXPERIMENTAL
Intervention: Astegolimab 490 mg
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Astegolimab 210 mg
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Astegolimab 70 mg
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Astegolimab 490 mg (eosinophil-low)
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Astegolimab 210 mg (eosinophil-low)
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Astegolimab 70 mg (eosinophil-low)
Number of subjects: 502

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 502
Study: 32481325

Group type: EXPERIMENTAL
Intervention: CTO-PCI group (PCI of the non-CTO artery concurrently with the CTO artery)
Number of subjects: 0

Group type: COMPARATOR
Intervention: non-CTO PCI group (PCI of only the non-CTO artery)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CTO-PCI group
Number of subjects: 0
Study: 35363301

Group type: EXPERIMENTAL
Intervention: Samotolisib (LY3023414) 200 mg twice daily plus enzalutamide 160 mg daily
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo plus enzalutamide 160 mg daily
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Samotolisib (LY3023414) plus enzalutamide
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo plus enzalutamide
Number of subjects: 142
Study: 32827413

Group type: EXPERIMENTAL
Intervention: Aromatherapy massage
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Olive-oil massage
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 75
Study: 34847073

Group type: EXPERIMENTAL
Intervention: Traditional resistance training
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Circular resistance training
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Interval resistance training
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 44
Study: 33495601

Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 528

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 528
Study: 33149022

Group type: EXPERIMENTAL
Intervention: Percutaneous tibial nerve stimulation plus medical treatment (arm A)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Medical treatment (arm B)
Number of subjects: 12
Study: 36153028

Group type: EXPERIMENTAL
Intervention: Early Adolescent Skills for Emotions (EASE) intervention, delivered in 7-weekly adolescent sessions and 3-biweekly caregiver sessions.
Number of subjects: 564

Group type: COMPARATOR
Intervention: Wait-list control arm (no intervention during the study period).
Number of subjects: 564
Study: 33047257

Group type: EXPERIMENTAL
Intervention: Chlorthalidone/amiloride (12.5/2.5 mg)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Losartan (50 mg)
Number of subjects: 97
Study: 32023372

Group type: EXPERIMENTAL
Intervention: 4400 IU of vitamin D3 per day during pregnancy
Number of subjects: 0

Group type: COMPARATOR
Intervention: 400 IU of vitamin D3 per day during pregnancy (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prenatal vitamin D supplementation
Number of subjects: 0
Study: 33170049

Group type: EXPERIMENTAL
Intervention: Game-Based Training (GBT)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Cognitive-Based Neuromuscular Training (CBNT)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 49
Study: 32277824

Group type: EXPERIMENTAL
Intervention: upadacitinib 7.5 mg
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: upadacitinib 15 mg
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: upadacitinib 30 mg
Number of subjects: 197

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: upadacitinib
Number of subjects: 197
Study: 33625673

Group type: EXPERIMENTAL
Intervention: Hydroxamate-based HDAC inhibitors using receptor-dependent 4D-QSAR model
Number of subjects: 0
Study: 33977947

Group type: EXPERIMENTAL
Intervention: 2S‐hesperidin (500 mg d‐1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (500 mg d‐1 microcellulose)
Number of subjects: 40
Study: 35236646

Group type: EXPERIMENTAL
Intervention: Butylphthalide treatment
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (conventional methods)
Number of subjects: 120
Study: 33289028

Group type: EXPERIMENTAL
Intervention: Core Elements of Outpatient Antibiotic Stewardship implementation
Number of subjects: 16712

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16712
Study: 32621263

Group type: EXPERIMENTAL
Intervention: Life Review Therapy and Memory Specificity Training (LRT‐MST)
Number of subjects: 64
Study: 33082178

Group type: EXPERIMENTAL
Intervention: Tailored letter incorporating patient's screening test results and treatment algorithms sent to family physician
Number of subjects: 148

Group type: COMPARATOR
Intervention: Generic letter without screening test results sent to family physician (Control)
Number of subjects: 148
Study: 35665782

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Number of subjects: 557

Group type: COMPARATOR
Intervention: Physician's choice of chemotherapy
Number of subjects: 557
Study: 34711220

Group type: EXPERIMENTAL
Intervention: Robotic Simulator (RS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Laparoscopic Simulator (LS)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Robotic Simulator (RS) and Laparoscopic Simulator (LS)
Number of subjects: 40
Study: 32616329

Group type: EXPERIMENTAL
Intervention: DAPT with clopidogrel and aspirin
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Serum levels of interleukin-18
Number of subjects: 22
Study: 34383540

Group type: EXPERIMENTAL
Intervention: Metacognitive interpersonal therapy-group (MIT-G)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) + waiting list
Number of subjects: 40
Study: 34270767

Group type: EXPERIMENTAL
Intervention: Tiered SB parenting model (Video Interaction Project and Family Check-Up)
Number of subjects: 403
Study: 35249173

Group type: EXPERIMENTAL
Intervention: Radiofrequency beauty device
Number of subjects: 33

Group type: COMPARATOR
Intervention: Anti-aging cosmetic
Number of subjects: 33
Study: 32171642

Group type: EXPERIMENTAL
Intervention: Specialised diabetes care (SDC)
Number of subjects: 287

Group type: COMPARATOR
Intervention: Primary care (PC)
Number of subjects: 287
Study: 33782719

Group type: EXPERIMENTAL
Intervention: Participants with essential tremor
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Gray matter morphological matrices
Number of subjects: 36

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 36
Study: 32990231

Group type: EXPERIMENTAL
Intervention: Straumann implant
Number of subjects: 86
Study: 35571447

Group type: EXPERIMENTAL
Intervention: Transbronchial cryo-biopsy (TBCB)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Transbronchial lung biopsy (TBLB)
Number of subjects: 152
Study: 34036705

Group type: EXPERIMENTAL
Intervention: Computerised cognitive training program (experimental group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study: 32959223

Group type: EXPERIMENTAL
Intervention: Ceratonia siliqua (carob) syrup twice a day for 3 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Vitamin E 100 mg twice a day for 3 months
Number of subjects: 60
Study: 32943404

Group type: EXPERIMENTAL
Intervention: Methylprednisolone pulse (intravenous injection, 250 mg·day‐1 for 3 days)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 68
Study: 36181769

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 4796

Group type: COMPARATOR
Intervention: Valsartan
Number of subjects: 4796